NASDAQ · Biotechnology · USD
Connect Biopharma Holdings Limited (CNTB) Stock Analysis
Connect Biopharma Holdings Limited (CNTB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CNTB Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.88
- Previous Close
- $0.88
- Day's Range
- 0.79–0.88
- 52-Week Range
- 0.85–3.82
- Volume
- 1.57M
Valuation
- Market Cap
- $55.12M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 18.66
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.19
Financials (FY)
- Revenue (FY)
- $64.00K−99.75%
- Net Income (FY)
- −$55.48M
- Shares Outstanding
- 62.97M
- 1-Year Return
- −52.78%
Dividend and dates
- Avg Volume
- 3.88M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CNTB closed at $0.80, −52.78% over 1 year.
Connect Biopharma Holdings Limited (CNTB) has a market capitalization of $55.12M.
In fiscal 2025, CNTB reported revenue of $64.00K.
CNTB Stock Return by Calendar Year
Connect Biopharma Holdings Limited (CNTB) return since Mar 2021: what $10,000 became
- 1 year
- $10,000 $4,722
- −52.78%
- 5 years
- $10,000 $452
- −95.48%
- Since Mar 2021
- $10,000 $432
- −95.68%
If you had invested $10,000 in Connect Biopharma Holdings Limited (CNTB) at the close on March 19, 2021, the earliest close on record here, it would have been worth $432 at the close on October 21, 2026: −95.68% in total, −43.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −71.70% |
| 2025 | +104.35% |
| 2024 | +16.95% |
| 2023 | +35.94% |
| 2022 | −83.15% |
| 2021 (partial year) | −72.15% |
As of October 21, 2026.
CNTB Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $64.00K | −$55.48M | −86,687.5% |
| 2024 | $26.03M | −$15.63M | −60.0% |
| 2023 | $0.00 | −$62.11M | — |
| 2022 | $0.00 | −$118.09M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $64.00K | — | −$58.07M | −$55.48M | −86,687.5% |
| 2024 | $26.03M | — | −$22.45M | −$15.63M | −60.0% |
| 2023 | $0.00 | — | −$69.06M | −$62.11M | — |
| 2022 | $0.00 | — | −$116.51M | −$118.09M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
CNTB Valuation vs Biotechnology Median
Median of 608 stocks| Metric | CNTB | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 18.66 | 13.30 | 40% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
YahooLeerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4
BenzingaHC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
BenzingaConnect Biopharma COPD Study Shows 81% Cut in Treatment Failures
MarketBeatHC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
BenzingaConnect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
InvestorsHub
All 20 articles ↓Show fewer ↑
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow
SeekingAlphaConnect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
BenzingaConnect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
SeekingAlphaBTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5
BenzingaConnect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
YahooConnect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85%
BenzingaConnect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
YahooOppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5
BenzingaHC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
BenzingaCanaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6
BenzingaConnect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
SeekingAlphaConnect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations - Slideshow
SeekingAlphaConnect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
InvestorsHubBTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B














